Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus SERNIVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus SERNIVO.
COR-OTICIN vs SERNIVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
1-2 drops in each affected ear twice daily for 7 days.
Apply a thin layer to affected area twice daily for up to 2 weeks.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Approximately 3 hours (parent drug); clinical duration extended via formulation.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid